News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,415 Results
Type
Article (2173)
Company Profile (13)
Press Release (19229)
Multimedia
Podcasts (5)
Webinars (1)
Section
Business (6294)
Career Advice (62)
Deals (853)
Drug Development (3666)
Employer Resources (3)
FDA (629)
Job Trends (775)
News (11028)
Policy (790)
Tag
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Standard (1)
2024 Biotech Beach Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (289)
Adcomms (2)
Allergies (1)
Alliances (1812)
ALS (18)
Alzheimer's disease (346)
Antibody-drug conjugate (ADC) (5)
Approvals (626)
Artificial intelligence (17)
Autoimmune disease (1)
Automation (2)
Bankruptcy (5)
Best Places to Work (749)
Biosimilars (2)
Biotechnology (13)
Brain cancer (4)
Cancer (38)
Cardiovascular disease (3)
Career advice (49)
Career pathing (2)
CAR-T (4)
Cell therapy (11)
Cervical cancer (1)
Clinical research (2837)
Collaboration (54)
Compensation (12)
Complete response letters (1)
COVID-19 (50)
C-suite (19)
Data (121)
Depression (28)
Diabetes (5)
Diagnostics (78)
Diversity, equity & inclusion (1)
Drug discovery (4)
Duchenne muscular dystrophy (7)
Earnings (1524)
Editorial (5)
Employer branding (1)
Employer resources (3)
Events (3083)
Executive appointments (57)
FDA (680)
Featured Employer (3)
Frontotemporal dementia (1)
Funding (48)
Gene therapy (12)
GLP-1 (29)
Government (79)
Guidances (4)
Healthcare (731)
Huntington's disease (4)
IgA nephropathy (1)
Immunology and inflammation (7)
Indications (1)
Infectious disease (50)
Inflammatory bowel disease (10)
Inflation Reduction Act (1)
Intellectual property (3)
Interviews (12)
IPO (338)
IRA (1)
Job creations (96)
Job search strategy (45)
Layoffs (25)
Legal (103)
Liver cancer (1)
Lung cancer (4)
Lymphoma (3)
Management (1)
Manufacturing (7)
Medical device (285)
Medtech (286)
Mergers & acquisitions (548)
Metabolic disorders (11)
Multiple sclerosis (23)
Neurodegenerative disease (24)
Neuropsychiatric disorders (12)
Neuroscience (540)
NextGen: Class of 2025 (242)
Non-profit (222)
Northern California (106)
Now hiring (3)
Obesity (6)
Opinion (10)
Ovarian cancer (3)
Pain (9)
Pancreatic cancer (2)
Parkinson's disease (42)
Patents (11)
Patient recruitment (4)
People (2703)
Pharmaceutical (2)
Phase I (662)
Phase II (1107)
Phase III (1273)
Pipeline (60)
Policy (4)
Postmarket research (140)
Preclinical (411)
Prostate cancer (1)
Psychedelics (7)
Radiopharmaceuticals (6)
Rare diseases (19)
Real estate (157)
Recruiting (1)
Regulatory (684)
Research institute (243)
Resumes & cover letters (9)
Rett syndrome (2)
Schizophrenia (38)
Series A (11)
Series B (4)
Sickle cell disease (2)
Southern California (178)
Special edition (3)
Spinal muscular atrophy (31)
Sponsored (2)
Startups (157)
Supply chain (1)
Tariffs (2)
The Weekly (5)
United States (1141)
Vaccines (8)
Venture capitalists (5)
Weight loss (4)
Date
Today (5)
Last 7 days (33)
Last 30 days (133)
Last 365 days (1613)
2025 (516)
2024 (1694)
2023 (1814)
2022 (2021)
2021 (2193)
2020 (1737)
2019 (1457)
2018 (1108)
2017 (1138)
2016 (1114)
2015 (1268)
2014 (884)
2013 (671)
2012 (648)
2011 (569)
2010 (484)
Location
Africa (18)
Arizona (5)
Arkansas (1)
Asia (1422)
Australia (184)
California (327)
Canada (116)
China (28)
Colorado (7)
Connecticut (27)
Delaware (1)
Europe (3478)
Florida (58)
Georgia (2)
Idaho (2)
Illinois (73)
Indiana (18)
Japan (8)
Kentucky (1)
Maine (4)
Maryland (35)
Massachusetts (263)
Michigan (1)
Minnesota (11)
Montana (1)
Nebraska (1)
Nevada (2)
New Hampshire (3)
New Jersey (60)
New Mexico (1)
New York (113)
North Carolina (14)
Northern California (106)
Ohio (8)
Pennsylvania (83)
Rhode Island (1)
South America (19)
South Carolina (1)
Southern California (178)
Tennessee (3)
Texas (16)
Utah (10)
Virginia (2)
Washington D.C. (5)
Washington State (23)
Wisconsin (2)
21,415 Results for "axon neuroscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Axonics, Inc. announced that its stockholders have voted to adopt Axonics’ merger agreement with Boston Scientific Corporation.
March 22, 2024
·
5 min read
Policy
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder.
May 16, 2024
·
6 min read
Press Releases
Boston Scientific Closes Acquisition of Axonics, Inc.
November 15, 2024
·
5 min read
Press Releases
Axonics Reports Third Quarter 2024 Financial Results
November 7, 2024
·
11 min read
Business
Axonics Reports First Quarter 2024 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.
April 30, 2024
·
11 min read
Neurodegenerative disease
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, which today began a rolling BLA for accelerated approval.
April 2, 2025
·
5 min read
·
Dan Samorodnitsky
Biotech Beach
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that the Axonics R20™ rechargeable sacral neuromodulation system has received CE Mark approval.
March 14, 2024
·
8 min read
Pipeline
AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.
April 29, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
April 22, 2025
·
1 min read
Gastroenterology Group of Naples Introduces Innovative Axonics Sacral Neuromodulation Therapy
Gastroenterology Group of Naples, a partner practice of United Digestive, is pleased to announce the introduction of Axonics Sacral Neuromodulation Therapy to its list of advanced treatment options for those suffering from fecal incontinence.
March 19, 2024
·
2 min read
1 of 2,142
Next
